Clinical trials for professionals

The objective of this research is to learn about the effects of an experimental drug called TransCon IL-2 ß/? when administered alone or in combination with pembrolizumab, chemotherapy ET or TransCon TLR7/8 agonist, or in combination with pembrolizumab and chemotherapy ET.

The objective of this trial is to determine safety and tolerability; to define the maximum tolerated dose (MTD) and recommended dose for Phase II (DRF2); and to evaluate the safety and tolerability of the step-up dosing schedule and DRF2 of BGB-11417, in monotherapy and in combination with zanubrutinib.

The purpose of this study is to better understand how an investigational drug called iberdomide (also known as BMS-986382 or CC-220) works to treat multiple myeloma, compared to lenalidomide (also known as Revlimid®), after you have undergone an autologous stem cell transplant (ASCT) and recovered, and your doctor feels it is appropriate to continue treatment to keep your myeloma under control. This is also called maintenance treatment.

The main goal of this study is to find the highest dose of BMI-F106C that is safe to give to people with advanced cancer, and to find out if this dose can make tumors stop growing (or shrink) and if cancer patients can live longer and feel better.

The purpose of this study is to determine the effects (good or bad) of the following: -Forimtamig administered alone, compared to -Forimtamig administered together with carfilzomib, compared to -Forimtamig administered together with daratumumab.

The purpose of the study is to collect clinical, brain imaging and neuropsychological data from patients with progressive supranuclear palsy or Parkinson's disease in order to analyze them, compare them with controls and draw conclusions about the pathological process involved in the cognitive, motor and psychiatric deficits of these diseases and thus advance their diagnosis and treatment. The results are of research interest only and for that reason you will be informed of the results only ...

The purpose of this study is to determine the appropriate dose of BI 765179 when administered alone and when administered in combination with ezabenlimab in patients with advanced cancer. This is the first time BI 765179 will be administered to humans. BI 765179 is an investigational drug that may treat cancer by interacting with the immune system. The immune system is the body's natural defense. The immune system sends cells called T-lymphocytes throughout the body to detect and fight infec...

The main objective of part 1G is to evaluate how well your body tolerates the study treatment (EOS-448 dostarlimab chemotherapy) and the efficacy of the study treatment on your tumor. The main objective of parts 2C and 2D is to evaluate the efficacy of the study treatment on your tumor and how well your body tolerates the study treatment (EOS-448 dostarlimab). The main objective of part 2E is to evaluate the efficacy of the study treatment on your tumor and how well your body tolerates the study...

The objective of this study is to examine an investigational drug, GFH925, when used in combination with an antineoplastic called "cetuximab", in people with a particular type of NSCLC, called "NSCLC with KRAS G12C mutation". The KRAS G12C mutation is a type of mutation of a group of genes that control cell growth and division. Genes are segments of deoxyribonucleic acid (DNA), which is present in most cells. Genes decide the function and actions of the cell. When mutated, th...